Source: Annual Congress 2011 - COPD management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Casaburi, J. Nakata, L. Bistrong, E. Torres, M. Rambod, J. Porszasz (Torrance, United States Of America). Treatment with megestrol acetate and testosterone increases body weight and muscle mass in COPD cachexia. Eur Respir J 2011; 38: Suppl. 55, 246

Member's Comments

No comment yet.

Related content which might interest you: Testosterone treatment increases fat-free mass, reduces fat mass and improves sexual function in men with COPD, in a 6-month randomized controlled trial Source: Eur Respir J 2003; 22: Suppl. 45, 537s Year: 2003 Influence of respiratory muscle strength and body weight on exercise metabolism in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 490s Year: 2001 Influence of body weight and fat mass on pulmonary function and performance status of COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 538s Year: 2003 Testosterone supplementation in men with COPD and muscle morphology Source: Eur Respir J 2005; 26: Suppl. 49, 659s Year: 2005 Late Breaking Abstract: SUN11031 (synthetic human ghrelin) improves lean body mass (LBM) and function in advanced COPD cachexia Source: Annual Congress 2010 - Pulmonary rehabilitation and chronic care: new developments in interventions, assessment and care Year: 2010 Effects of steroid treatment on serum leptin level and haemostatic parameters in COPD patients with normal body mass index Source: Eur Respir J 2006; 28: Suppl. 50, 30s Year: 2006 Effects of pulmonary rehabilitation in patients with COPD with and without fat free mass depletion Source: Annual Congress 2012 - The best posters in pulmonary rehabilitation and chronic care Year: 2012 Inflammatory markers in skeletal muscle of low and normal weight COPD patients Source: Annual Congress 2005 - Systemic effects of COPD Year: 2005 Association of weight loss in COPD patients with low body mass index on outcomes Source: Annual Congress 2011 - Challenges in chronic disease management: helping individuals with chronic lung disease remain stable Year: 2011 Whole-body resting and exercise-induced lipolysis in sarcopaenic patients with COPD Source: Eur Respir J 2008; 32: 1466-1471 Year: 2008 Decreased body mass index in COPD is associated with quantity of emphysema Source: Annual Congress 2004 - Exercise and systemic effects in COPD Year: 2004 Low fat-free mass and body mass index are associated with worse survival in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Assessment of nutrition and muscle mass loss in patients with severe COPD. Source: International Congress 2017 – Markers of COPD progression Year: 2017 Are systemic inflammatory markers predictive of loss of lean body mass in COPD patients? Source: Annual Congress 2011 - Comorbidities and impact on society of asthma and COPD Year: 2011 Lean body mass is positively associated with lung function at age 15 Source: International Congress 2017 – Determinants of childhood asthma and atopy Year: 2017 Influence of the body mass index on the survival of COPD patients Source: International Congress 2019 – Long-term evaluation and control of airway diseases Year: 2019 Predictors of body mass index and body fat after lung and heart transplantation Source: Annual Congress 2010 - Novel biomarkers and old parameters in approaching pulmonary diseases Year: 2010 Altered muscle metabolism and muscle mass in patients with COPD Source: International Congress 2017 – Neuromuscular consequences of respiratory diseases Year: 2017 The effect of resveratrol on muscle and fat metabolic health in COPD Source: International Congress 2019 – Novel methods, diagnostics and biomarkers in chronic lung diseases Year: 2019 Effect of body mass index on exercise as an asthma trigger Source: Annual Congress 2008 - Markers and triggers of asthma Year: 2008